Because of the very high penetrance and rapid onset of neuroblastoma in our nf1-deficient, MYCN-transgenic zebrafish model, it becomes one of a very few systems in which extensive analysis of the synergistic activity of two or more drugs can be evaluated in primary tumors in vivo. This evidence concerns the gene NF1 and neuroblastoma.